Company / Capital Expenditures
Lipocine Inc. Capital Expenditures History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$90.1K
FY2025
5-year range
$7.6K / $133.8K
FY2021-FY2025
Trend
+584.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +584% YoY in FY2025, a notable deviation from the 6-year average annual change of +409%.
Based on SEC 10-K filings.
$90,086 in FY2025 with a 3-year CAGR of +128.1%.
Declined from $133,831 to $90,086 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +128.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +128.1%, indicating consistent growth.
- In FY2025, capital expenditures increased 584.2% year-over-year.
- Peak capital expenditures was recorded in FY2023.
- Lowest capital expenditures in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.16 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $90.1K | +584.2% |
| FY2024 | $13.2K | -90.2% |
| FY2023 | $133.8K | +1663.0% |
| FY2022 | $7.6K | +0.0% |
| FY2021 | $7.6K | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $59.6K | +384.3% |
| FY2013 | $12.3K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026